The Medicines Co. briefing documents mixed, says Jefferies Jefferies views the briefing documents for The Medicines Co.'s cangrelor as mixed with one reviewer recommending against approval and one for approval. The firm thinks the dose and timing of the loading dose will be a key topic of discussion at the advisory meeting on Wednesday and keeps a Buy rating on The Medicines Co.
News For MDCO From The Last 14 Days
Check below for free stories on MDCO the last two weeks.
The Medicines Co. announces FDA BLA acceptance for Fibrocaps, The Medicines Co. announced that the U.S. Food and Drug Administration has accepted the filing of a biologic license application for the investigational hemostatic agent Fibrocaps, a dry powder formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery, where control of mild or moderate bleeding by conventional means is ineffective or impractical. The FDA action date for Fibrocaps is January 31, 2015.
On The Fly: Analyst Downgrade Summary ArcelorMittal (MT) downgraded to Neutral from Outperform at Credit Suisse... Essex Property Trust (ESS) downgraded to Neutral from Buy at Goldman... Healthstream (HSTM) downgraded to Market Perform from Outperform at Northland... Imperial Oil (IMO) downgraded to Underperform from Neutral at BofA/Merrill... Nordion (NDZ) downgraded to Hold from Buy at Canaccord... The Medicines Co. (MDCO) downgraded to Neutral from Overweight at Piper Jaffray... U.S. Bancorp (USB) downgraded to Hold from Buy at Sandler O'Neill... Old National Bancorp (ONB) downgraded to Hold from Buy at Sandler O'Neill... Edison International (EIX) downgraded to Hold from Buy at Argus.
The Medicines Co. downgraded to Neutral from Overweight at Piper Jaffray Piper Jaffray downgraded The Medicines Co. (MDCO) to Neutral after a court ruled the company failed to prove its patents were infringed by Hospira (HSP).